Effective early detection and optimal management are critical in preventing high-grade interstitial lung disease, a treatment-related adverse effect of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic breast cancer.
Experts discuss the FDA’s call for a boxed warning for secondary T-cell malignancies on all approved CAR T-cell agents in late January 2024.
Eric S. Christenson, MD, discusses the potential benefit of copanlisib plus nivolumab in PIK3CA-mutant microsatellite stable colorectal cancer.
Vikram Narayan, MD, details the mechanism of action of the nadofaragene firadenovec and how the agent is impacting care for patients with BCG-unresponsive non–muscle invasive…
Patients with chronic lymphocytic leukemia who initiated therapy through an integrated health-system specialty pharmacy had high therapy adherence rates.
Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma.
The European Medicines Agency has granted orphan drug designation to annamycin for the treatment of patients with acute myeloid leukemia.
The FDA has approved the optical imaging agent Lumisight and the Lumicell Direct Visualization System for use in fluorescence imaging in breast cancer.
Anne Favret, MD discusses the FDA approval of capivasertib in combination with fulvestrant for HR-positive, HER2-negative breast cancer.
Updated phase 1 findings with botensilimab/balstilimab in MSS/pMMR mCRC show that the regimen elicited respective 12- and 18-month OS rates of 71% and 62%.
The FDA has received a type C meeting request from Oncolytics Biotech to discuss a registration-enabling trial for pelareorep in HR+/HER2– breast cancer.
